Quotient Sciences Extends Ipsen FOP Supply Deal

Quotient Sciences has announced an extended commercial supply partnership with Ipsen to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare and debilitating genetic disorder that affects fewer than 1,000 people worldwide.

The collaboration centers on the continued production of Sohonos (palovarotene), a highly potent therapy approved by the U.S. Food and Drug Administration in 2023 for the treatment of FOP. The condition is characterized by the abnormal formation of bone in muscles, tendons and other connective tissues, leading to progressive immobility and severe complications. Given the rarity of the disease and the complexity of manufacturing highly potent active pharmaceutical ingredients (HPAPIs), sustained and specialized production capabilities are essential.

Under the expanded partnership, Ipsen has invested in advanced equipment at Quotient Sciences’ Boothwyn, Pennsylvania facility to strengthen manufacturing capacity and safety controls. The upgrades include a Pneumatic Closed Transfer System designed to ensure safe material handling without compromising blend uniformity, as well as a Flexible Dispensing Isolator to enhance operator protection and remove the need for specialized cleaning procedures.

These enhancements expand Quotient Sciences’ capabilities to manage and manufacture highly potent drug substances with occupational exposure limits (OELs) at or below 1 µg/m³. The infrastructure allows seamless integration with existing systems while ensuring strict containment standards required for potent compounds such as palovarotene.

Quotient Sciences, an integrated contract research, development and manufacturing organization (CRDMO), said the partnership reflects its focus on supporting niche and low-volume commercial products that are often deprioritized by larger CDMOs. The company emphasized its experience in global supply management, including handling complex logistics and ensuring reliable distribution of specialized therapies to patients worldwide.

Marlene Leuenberger, Vice President and General Manager of Quotient Sciences’ Philadelphia operations, noted that the investment underscores the company’s commitment to serving ultra-rare disease communities. She highlighted that expanding containment and manufacturing capabilities not only secures supply of Sohonos for the FOP community but also strengthens the company’s broader ability to support other highly potent compounds at commercial scale.

For Ipsen, the extended agreement ensures continuity of supply for a therapy that addresses a significant unmet need in a small but vulnerable patient population. The collaboration demonstrates how targeted infrastructure investments and specialized expertise can help sustain access to life-changing medicines in rare diseases.